Met Life Investment Management, LLC Lineage Cell Therapeutics, Inc. Transaction History

Met Life Investment Management, LLC

$17.1 Billion
Q3 2024

18 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2024 Aug 13, 2024	BUY	$0.89 - $1.47 $7,540 - $12,453	8,472 Added 12.15%	78,181 $78,000
Q1 2024 May 14, 2024	BUY	$0.86 - $1.48 $59,949 - $103,169	69,709 New	69,709 $103,000
Q3 2023 May 09, 2024	BUY	$1.16 - $1.53 $79,754 - $105,193	68,754 New	68,754 $81,000
Q2 2023 Apr 29, 2024	BUY	$1.26 - $1.53 $86,630 - $105,193	68,754 New	68,754 $96,000
Q2 2023 Aug 10, 2023	BUY	$1.26 - $1.53 $86,630 - $105,193	68,754 New	68,754 $96,000
Q1 2022 May 12, 2022	SELL	$1.21 - $2.48 $59,748 - $122,459	-49,379 Closed	0 $0
Q4 2021 May 17, 2024	BUY	$1.84 - $2.68 $60,263 - $87,775	32,752 Added 196.98%	49,379 $120,000
Q4 2021 Jun 21, 2023	BUY	$1.84 - $2.68 $90,857 - $132,335	49,379 New	49,379 $120,000
Q4 2021 Mar 22, 2023	BUY	$1.84 - $2.68 $60,263 - $87,775	32,752 Added 196.98%	49,379 $120,000
Q4 2021 Feb 15, 2022	BUY	$1.84 - $2.68 $60,263 - $87,775	32,752 Added 196.98%	49,379 $121,000
Q3 2021 May 17, 2024	SELL	$2.26 - $2.86 $76,686 - $97,045	-33,932 Reduced 67.11%	16,627 $41,000
Q3 2021 Jun 21, 2023	BUY	$2.26 - $2.86 $37,577 - $47,553	16,627 New	16,627 $41,000
Q3 2021 Mar 22, 2023	SELL	$2.26 - $2.86 $76,686 - $97,045	-33,932 Reduced 67.11%	16,627 $41,000
Q3 2021 Nov 15, 2021	SELL	$2.26 - $2.86 $76,686 - $97,045	-33,932 Reduced 67.11%	16,627 $42,000
Q2 2021 May 17, 2024	SELL	$2.17 - $3.0 $41,555 - $57,450	-19,150 Reduced 27.47%	50,559 $144,000
Q2 2021 Jun 21, 2023	BUY	$2.17 - $3.0 $109,713 - $151,677	50,559 New	50,559 $144,000
Q2 2021 Mar 22, 2023	BUY	$2.17 - $3.0 $109,713 - $151,677	50,559 New	50,559 $144,000
Q2 2021 Aug 16, 2021	BUY	$2.17 - $3.0 $109,713 - $151,677	50,559 New	50,559 $144,000

Others Institutions Holding LCTX

# of Institutions

123

Shares Held

95.2M

Call Options Held

63.8K

Put Options Held

View Full List

About Lineage Cell Therapeutics, Inc.

Ticker LCTX
Exchange NYSE
Sector Healthcare
Industry Biotechnology
Shares Outstandng 169,755,008
Market Cap $109M
Description
Lineage Cell Therapeutics, Inc., a clinical-stage biotechnology company, develops novel cell therapies for the treatment of degenerative diseases in the United States and internationally. The company develops OpRegen, a retinal pigment epithelium cell replacement therapy, which is in Phase I/IIa clinical trial for the treatment of the dry age-re...

More about LCTX

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Met Life Investment Management, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Met Life Investment Management, LLC with notifications on news.

Account